Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mevacor “Pharmacy Care” Tactic Insufficient To Ensure Compliance – Panel

This article was originally published in The Tan Sheet

Executive Summary

The American Pharmacists Association's proposed "pharmacy care" model fell short of convincing FDA advisory panelists to recommend OTC status for Mevacor Daily

You may also be interested in...

Mevacor OTC Panel Rejection Elicits Third Drug Class Talk

A joint FDA panel decision to recommend against approval of over-the-counter Mevacor Daily was tempered by the endorsement of a behind-the-counter drug class by a number of panelists

Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins

A cholesterol self-management program for OTC Mevacor was effective in deterring consumers from improperly purchasing the nonprescription version of the cholesterol-lowering drug, results from the CUSTOM actual-use study show

“Pharmacy Care” OTC Category Considered By APhA Task Force

A new category of "pharmacy care" drugs could broaden access to certain over-the-counter drugs, according to the American Pharmacists Association


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts